Fused thiochromeno[4,3-d]isoxazoles: One-pot synthesis, antibacterial, antibiofilim, and in silico studies
Journal of Molecular Structure, ISSN: 0022-2860, Vol: 1325
2025
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
In this study, we designed and synthesized several novel fused isoxazole derivatives using a single [3 + 2] reaction cycloaddition reaction of 4-((3-iodoprop-2-yn-1-yl)sulfonyl)-N,N-dimethylaniline followed by C-C bond coupling with various nitrile oxides in a PEG-400 under microwave conditions. Later, Minimum Inhibitory Concentration of the newly synthesized compounds (6a–6p) was determined against three G+ve bacterial strains, B. subtilis, S. aureus, and S. epidermidis. When compared to the reference molecule, dicloxacillin, the majority of the compounds demonstrated adequate efficacy. Among the compounds investigated, compounds 6f, 6g, 6h, 6j, and 6k demonstrated the most promising MIC values compared to others. The MIC values ranged from 1.56 µg to 12.5 µg, especially compounds 6f and 6k, which displayed superior activity against B. subtilis and S. aureus strains compared to the standard dicloxacillin. We also documented the results of anti-biofilm profiles for the compounds 6f, 6g, 6h, 6j, and 6k. Based on the result, we noted that, the active derivatives 6f and 6k strongly inhibited the biofilm of B. subtilis and S. aureus biofilm growth, with BFIC values ranging from 2.89 ± 0.21 µg/mL to 5.94 ± 0.32 (P<0.001) µg/mL. Our further aim is the time-kill studies of the human pathogenic organism using 6f and 6k compounds. Docking simulations also performed on the MRSA PBP2a (PDB: 1MWT) of more potent compounds consistently formed three hydrogen bond interactions with the active site residues SER598, HIS583, and SER643.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know